undamentalytics Newsletter
Sign in

Canopy Growth Corp (CGC) stock

Add to watchlist

Add holding +

NASDAQ: CGC Nasdaq Pharmaceuticals Next results ~November 6, 2026

Canopy Growth Corp is a US-listed company in the pharmaceuticals industry. Its financial year ends in March.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 7 selling0 purchases and 21 sales by directors and officers, last 12 monthsInsider trades
  • Funds68 adding, 62 cuttingOf 11 active managers that changed their stake, 7 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 6, 2026 (estimated)

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 43% in the quarter to 2026-06-30, the 2nd beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Canopy Growth Corp's latest figures clears our strength thresholds.

Things to watch

  • Results due soon. Results are expected around 6 November; the share price can move sharply on the day.
  • Share dilution. Diluted shares rose 10.2% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 81% and a beta of 1.2 against the S&P 500.

Latest results

Earnings per share
-$0.02 against an average estimate of -$0.03: beat by 43.3%
Share reaction
+2.1% in the first session after the results on August 7, 2026, against +0.6% for the S&P 500
Next report
November 6, 2026; average EPS estimate -$0.03

Canopy Growth's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+4.3%
  • 1 week+1.9%
  • 1 month-22.2%
  • This year-40.3%
  • 1 year-45.1%
  • 5 years-99.5%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 7, 2026
Next results (est.)
November 6, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Shareholder vote
  2. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Canopy Growth Corp valuation models and calculator

No model value for Canopy Growth Corp at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Valuation models

We value Canopy Growth Corp as an operating company, with every model that fits that kind of business. Cost of equity 10.1%: the 10-year Treasury yield (4.9%) plus a beta of 1.14 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no twelve-month earnings or share count in the filings yet
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: no twelve-month earnings or share count in the filings yet
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: no twelve-month earnings or share count in the filings yet
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. — Does not apply: no twelve-month earnings or share count in the filings yet
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. — No model applies: the filings don’t yet support a value.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Canopy Growth Corp with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 6, 2026, before the open. Analysts expect revenue of $82m and EPS of −$0.03 (range −$0.03 to −$0.03) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.07 +87% $338m +19%
Next −$0.17 −143% $364m +8%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −66.7% on 90 days ago. In the last 30 days, 0 analysts raised Canopy Growth Corp's forecast and 0 cut it.

Consensus EPS forecast Canopy Growth Corp, last 90 days
−$0.30 −$0.20 −$0.10 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.21 Current fiscal year, 60 days ago: −$0.07 Current fiscal year, 30 days ago: −$0.07 Current fiscal year, 7 days ago: −$0.07 Current fiscal year, Now: −$0.07 −$0.07 Next fiscal year, 90 days ago: −$0.17 Next fiscal year, 60 days ago: −$0.17 Next fiscal year, 30 days ago: −$0.17 Next fiscal year, 7 days ago: −$0.17 Next fiscal year, Now: −$0.17 −$0.17

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.21−$0.17
60 days ago −$0.07−$0.17
30 days ago −$0.07−$0.17
7 days ago −$0.07−$0.17
Now −$0.07−$0.17

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.03 −$0.02 +43.3%
Dec 2025 −$0.05 −$0.14 −183.2%
Sept 2025 −$0.11 $0.00 +102.7%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

8 analysts, Oct 2026
Buy225%
Hold675%
Sell00%

Monthly trend

  1. Oct 2026268
  2. Sep 2026268
  3. Aug 2026268

Counts of recommendations published by analysts covering Canopy Growth Corp, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
7.5%
of tradable shares
Days to cover
12.61
at average volume
Short interest, 1 month
+13%
to October 15, 2026
Held by institutions
8%
of shares
Held by insiders
0.2%
of shares
Employees
1,128
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
CGC−65%−74%−78%−46%−58%−40%
Industry peers (median)−18%−49%−13%−2%+9%−12%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
CGC8%25%33%25%17%36%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
CGC−83%−78%−88%−82%−72%−53%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 100% from October 15, 2018 to October 30, 2026. Getting back needed a 87021% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.65 – $1.92
From 52-week high
−64.5%
vs 50-day average
−21.1%
vs 200-day average
−31.7%
Volatility (1 year)
81%
Beta vs S&P 500
1.17

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±14.2%
After a week
3 up, 9 down
typical move ±10.3%
After a month
4 up, 8 down
typical move ±23.6%
Results releasedNext dayS&P 500 next day5 days21 days
August 7, 2026 +2.1% +0.6% +9.4% +3.6%
June 15, 2026 −4.2% +1.2% −5.4% −7.3%
February 6, 2026 +0.9% +2.4% 0.0% −1.9%
November 7, 2025 +16.5% +1.7% −1.8% +3.7%
August 8, 2025 +50.5% +0.6% +23.8% +38.1%
May 30, 2025 −29.2% +0.5% −0.6% −33.9%
February 7, 2025 −29.3% −0.2% −32.0% −60.4%
November 8, 2024 −11.2% +0.5% −18.0% −23.5%
August 9, 2024 −8.3% +0.5% +1.7% −30.6%
May 30, 2024 +0.6% +0.2% −15.7% −24.6%
February 9, 2024 −7.5% +0.5% −7.1% −29.0%
November 9, 2023 −10.3% +0.8% −8.6% +26.2%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 40-F. Generated November 3, 2026. Definitions in our methodology.

Where the revenue comes from

Fiscal year to March 31, 2026
Segments
Line of business Revenue YoY
Cannabis Net Revenue $214M ▲ 14.6%
Cannabis $214M ▲ 14.6%
Storz and Bickel $70.7M ▼ 14.1%
This Works $0 —
All Other Segments $0 —

These categories overlap or exclude eliminations, so shares aren't shown.

Products and services
Line of business Revenue YoY
Storz Bickel $70.7M ▼ 14.1%
International Markets Cannabis $28.7M ▼ 7.2%
This Work $0 —
Other Revenue $0 —

These categories overlap or exclude eliminations, so shares aren't shown.

Geography
Region Revenue YoY
Canada $186M ▲ 19.4%
Germany $62.1M ▲ 3.6%
United States $28.3M ▼ 21.5%
Other Geographical Area $8.2M ▼ 52.5%

These categories overlap or exclude eliminations, so shares aren't shown.

From Canopy Growth Corp's 10-K filed June 15, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$28.2M
Institutions reporting
209
Shares held vs prior quarter
▲ 0.1%
Positions opened / closed
25 / 30

Top buyers and sellers, Q2 2026: 68 institutions bought and 62 sold ; the biggest buyer was Tidal Investments LLC (+710K shares) and the biggest seller Citadel Advisors LLC (−1.1M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Tidal Investments LLC $8.7M 9.2M 30.9% ▲ 8.4%
Morgan Stanley $1.8M 1.9M 6.6% ▼ 1.2%
Lazard Asset Management LLC $1.8M 1.8M 6.2% ▲ 2.2%
Jane Street Group, LLC $1.5M 1.6M 5.4% ▼ 1.2%
UBS Group AG $1.3M 1.4M 4.7% ▲ 48.6%
Goldman Sachs Group Inc $1.2M 1.3M 4.4% ▲ 3.2%
Susquehanna International Group, LLP $1.2M 1.2M 4.1% ▲ 24.3%
Royal Bank Of Canada $1M 1.1M 3.6% ▲ 10.9%
National Bank Of Canada $816,023 858K 2.9% ▲ 6.0%
HRT Financial LP $679,000 715K 2.4% ▲ 124.9%
TD Asset Management Inc $667,871 687K 2.4% ▲ 34.5%
Mackenzie Financial Corp $658,674 477K 2.3% ▲ 37.2%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Canopy Growth Corp's complete shareholder register. Values are as reported by the filers ; 3 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $393,357 21 trades by 7 insiders · 0% under pre-set plans
Net ▼ $393,357 net selling
Insider Date Trade Shares Price Value
Atkins M Shan Director September 28, 2026 Sell 3,096 $0.93 $2,879
Bayern Joseph Director September 28, 2026 Sell 3,096 $0.93 $2,879
Lazzarato David Angelo Director September 28, 2026 Sell 22,380 $0.93 $20,813
Yanofsky Theresa Director September 28, 2026 Sell 14,920 $0.93 $13,876
Stewart Thomas Carlton See Remarks September 17, 2026 Sell 25,755 $0.93 $23,952
Stewart Thomas Carlton See Remarks August 24, 2026 Sell 2,231 $1.47 $3,280
Gedeon Christelle See Remarks August 24, 2026 Sell 13,344 $1.47 $19,616
Lazzarato David Angelo Director June 26, 2026 Sell 22,674 $0.92 $20,860
Atkins M Shan Director June 26, 2026 Sell 3,197 $0.92 $2,941
Yanofsky Theresa Director June 26, 2026 Sell 15,054 $0.92 $13,850
Bayern Joseph Director June 26, 2026 Sell 3,197 $0.92 $2,941
Mongeau Luc Chief Executive Officer June 17, 2026 Sell 135,231 $0.97 $131,174

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 5 trades and filings

No trades in Canopy Growth Corp disclosed in the last 12 months; 5 earlier trades on record.

  • John A. Yarmuth(D-KY 3):Purchase, $1,001 - $15,000, traded February 12, 2021, filed February 19, 2021
  • John A. Yarmuth(D-KY 3):Purchase, $1,001 - $15,000, traded November 5, 2020, filed November 15, 2020
  • John A. Yarmuth(D-KY 3):Purchase, $1,001 - $15,000, traded March 10, 2020, filed August 11, 2021

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around November 6, 2026 estimated from the company's past filing pattern, not announced

  • August 7, 2026
  • June 15, 2026
  • February 6, 2026
  • November 7, 2025
  • August 8, 2025
  • May 30, 2025

Recent SEC filings

Data status

When each part of this page on Canopy Growth Corp was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Canopy Growth Corp in brief

What does Canopy Growth Corp do?
Canopy Growth Corp is a US-listed company in the pharmaceuticals industry. Its financial year ends in March.
What is Canopy Growth Corp's stock ticker?
Canopy Growth Corp trades under the ticker CGC on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Canopy Growth Corp's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Tidal Investments LLC, Morgan Stanley and Lazard Asset Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Canopy Growth Corp stock?
Over the last 12 months, Canopy Growth Corp's directors and officers reported 0 open-market purchases and 21 sales on Form 4. The insider trading page charts every trade.
When is Canopy Growth Corp's next earnings date?
Around November 6, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Canopy Growth Corp announces its own schedule.